Efficacy and safety of ixekizumab through 5 years in moderate-to-severe psoriasis: long-term results from the UNCOVER-1 and UNCOVER-2 phase-3 randomized …

C Leonardi, K Reich, P Foley, H Torii, S Gerdes… - Dermatology and …, 2020 - Springer
Introduction Ixekizumab, a high-affinity monoclonal antibody that selectively targets
interleukin-17A, is approved for treatment of moderate-to-severe plaque psoriasis. Our …

Proposal of a new scoring formula for the Dermatology Life Quality Index in psoriasis

F Rencz, L Gulácsi, M Péntek, AK Poór… - British Journal of …, 2018 - academic.oup.com
Summary Background 'Not relevant'responses (NRRs) on the Dermatology Life Quality
Index (DLQI) may occur in up to 40% of patients with psoriasis. As these responses are …

Correlation between change in psoriasis area and severity index and dermatology life quality index in patients with psoriasis: pooled analysis from four phase 3 …

K Houghton, D Patil, B Gomez, SR Feldman - Dermatology and Therapy, 2021 - Springer
Abstract Introduction Patients with psoriasis (PsO) experience impaired health-related
quality of life due to physical and psychosocial burdens. The objective of this study was to …

Impact of atopic dermatitis on work and activity impairment in Taiwan

CC Tom, LIN Yi-Chun, CHO Yung-Tsu… - Acta dermato …, 2021 - pmc.ncbi.nlm.nih.gov
Atopic dermatitis has a substantial impact on work and activity impairment according to
studies from Western communities. Prospective studies of work productivity and activity …

[HTML][HTML] A systematic review of 207 studies describing validation aspects of the dermatology life quality index

V Jui, JR Johns, MALI Faraz, JR Ingram… - Acta Dermato …, 2024 - pmc.ncbi.nlm.nih.gov
This study systematically analysed peer-reviewed publications describing validation aspects
of the Dermatology Life Quality Index (DLQI) and used Naicker's Critically Appraising for …

Psoriasis in difficult to treat areas: treatment role in improving health-related quality of life and perception of the disease stigma

C Lanna, C Galluzzi, A Zangrilli, M Bavetta… - Journal of …, 2022 - Taylor & Francis
Background When psoriasis affects scalp, nails, palms and soles, it is considered difficult to
treat and causes severe impairment of life quality. Objective We evaluated which difficult site …

[HTML][HTML] Patient-reported outcomes are important elements of psoriasis treatment decision making: a discrete choice experiment survey of dermatologists in the United …

SR Feldman, SA Regnier, A Chirilov, F Hey… - Journal of the American …, 2019 - Elsevier
Background Psoriasis Area and Severity Index (PASI) response rates have been the
benchmark for evaluating treatment efficacy in trials involving moderate-to-severe psoriasis …

Secukinumab provides rapid relief from itching and pain in patients with moderate-to-severe psoriasis: patient symptom diary data from two phase 3, randomized …

G Yosipovitch, J Soung, J Weiss… - Acta dermato …, 2019 - medicaljournalssweden.se
METHODS AND RESULTS Full details of the study designs and patient enrollment criteria
for ERASURE and FIXTURE have been described previously (6). Patient-reported itching …

[HTML][HTML] Itch as a critical factor in impaired health-related quality of life in patients with plaque psoriasis achieving clear or almost-clear skin: Analysis of the single-arm …

T Miyagi, Y Kanai, K Murotani, Y Okubo, M Honma… - JAAD international, 2022 - Elsevier
Background Patients with psoriasis report impaired health-related quality of life (HRQoL;
Dermatology Life Quality Index score≥ 2) even after achieving clear or almost-clear skin …

[PDF][PDF] Assessing the impact of improvements in PASI and itch scores on patients' quality of life in the treatment of psoriasis

G Yosipovitch, Y Dong, R Burge… - Acta dermato …, 2019 - pdfs.semanticscholar.org
RESULTS Overall, integrated data from 2,570 patients (PBO= 361; ETN= 740; and IXE
Q4W= 733 and IXE Q2W= 736) were included in this analysis. Details of patient disposition …